Mevrometostat not checked

Pfizer · PF-06821497 · EZH2i

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
4 active
7 in total · 6 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Metastatic Castrate Resistant Prostate Cancer (mCRPC), Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate, Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC) and 1 more
Main trialPhase 3
“Pfizer MEVPRO-1 (C2321014) is a randomized, open-label, multi-center clinical trial evaluating whether combining the study medicine (PF-06821497) with enzalutamide is safe and effective compared to physician's choice of either second-line androgen receptor (AR) directed therapy with enzalutamide or docetaxel (chemotherapy) for treating metastatic castration-resistant prostate cancer (mCRPC) after progression on prior abiraterone acetate treatment. The primary objective of this clinical trial is to assess the radiographic progression free survival (rPFS) of the combination of PF-06821497 plus…”In the company’s words, NCT06551324 on ClinicalTrials.gov
Other names
PF-06821497 · EZH2i

Other drugs for Metastatic Castrate Resistant Prostate Cancer (mCRPC)

All 195 drugs for Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Coming up4

Changes1

Last 90 days

Trials7

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 28 Feb 2027 A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
Phase 3Active, not recruiting 30 Sep 2027 A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Phase 3Recruiting 12 Sep 2028 This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Phase 1Recruiting 20 Apr 2028 A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Phase 1Completed 20 Jun 2023 A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants.
Phase 1Completed 11 Nov 2024 A Study to Learn How the Medicine Called [14C] PF-06821497 is Taken up Into and Removed From the Body.
Phase 1Withdrawn 8 Sep 2025 A Study to Learn How Different Tablets of the Study Medicine Mevrometostat Are Taken up Into the Blood in Healthy Adults
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Mevrometostat

Following is part of Solo: you see every change to Mevrometostat the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in